--- title: "Lipocine (LPCN) news: offering" url: "https://aibio.space/companies/lipocine/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "LPCN offering news: Lipocine raises its at-the-market program to $50,000,000. Lipocine Inc. (NASDAQ: LPCN), United States." --- LPCN Lipocine Inc. NASDAQ · United States # Lipocine (LPCN) news LPCN offering news Financings · 2026-02-26 ## [Lipocine raises its at-the-market program to $50,000,000](https://aibio.space/news/lipocine-raises-market-program-50-000-000/) Lipocine Inc. filed a prospectus supplement on February 26, 2026 under its sales agreement with A.G.P./Alliance Global Partners. It had sold $10,615,576 of stock under the earlier registration. ## Latest Lipocine news We have not published a story on Lipocine yet. When there is news, it will appear here. ## Lipocine at a glance - **Ticker**: LPCN - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $23.3 million ### Related companies - [Cocrystal Pharma](https://aibio.space/companies/cocrystal-pharma/) NASDAQ: COCP - [SELLAS Life Sciences Group](https://aibio.space/companies/sellas-life-sciences/) NASDAQ: SLS - [Vertex Pharmaceuticals](https://aibio.space/companies/vertex-pharmaceuticals/) NASDAQ: VRTX - [Incyte](https://aibio.space/companies/incyte/) NASDAQ: INCY - [AN2 Therapeutics](https://aibio.space/companies/an2-therapeutics/) NASDAQ: ANTX - [Aligos Therapeutics](https://aibio.space/companies/aligos-therapeutics/) NASDAQ: ALGS - [AIM ImmunoTech](https://aibio.space/companies/aim-immunotech/) AMEX: AIM - [Bristol-Myers Squibb](https://aibio.space/companies/bristol-myers-squibb/) NYSE: BMY ### Also on NASDAQ - [Rigel Pharmaceuticals](https://aibio.space/companies/rigel-pharmaceuticals/) RIGL - [Bicycle Therapeutics](https://aibio.space/companies/bicycle-therapeutics/) BCYC - [OneMedNet](https://aibio.space/companies/onemednet/) ONMD - [Kardigan](https://aibio.space/companies/kardigan/) KARD - [Incyte](https://aibio.space/companies/incyte/) INCY - [Apyx Medical](https://aibio.space/companies/apyx-medical/) APYX ## What Lipocine does Lipocine Inc. is a biopharmaceutical company that uses a proprietary technology platform to develop products with effective oral delivery of previously difficult to deliver molecules. Its lead product, TLANDO, is an oral treatment for testosterone replacement therapy in adult males with a deficiency or absence of endogenous testosterone, comprised of testosterone undecanoate. The company has licensed TLANDO to Verity Pharmaceuticals for the United States and Canada, to SPC Korea Limited for South Korea, to Pharmalink for the Gulf Cooperation Council countries, and to Aché for Brazil. It retains development and commercialization rights for TLANDO outside those territories. Its clinical development pipeline includes LPCN 1154 for postpartum depression, LPCN 2201 for major depressive disorder, LPCN 2203 for essential tremor, LPCN 2101 for epilepsy and LPCN 2401 for improved body composition in obesity management. Its focus areas also include liver disease and hormone supplementation for men and women. The company expects to seek partnerships for assets including LPCN 1148, a novel prodrug of testosterone and testosterone laurate. | Product or program | What it is | Stage | |---|---|---| | TLANDO | Oral testosterone undecanoate for testosterone replacement therapy in adult males | Licensed to commercial partners in several territories | | LPCN 1111 (TLANDO XR) | Once-daily oral testosterone tridecanoate for testosterone replacement therapy | Licensed to Verity for the United States and Canada | | LPCN 1154 | Oral candidate for postpartum depression | Clinical development pipeline candidate | | LPCN 2201 | Oral candidate for major depressive disorder | Clinical development pipeline candidate | | LPCN 2203 | Oral candidate for essential tremor | Clinical development pipeline candidate | | LPCN 2101 | Oral candidate for epilepsy | Clinical development pipeline candidate | Summarised from the company's [10-K filed Mar 10, 2026](https://www.sec.gov/Archives/edgar/data/1535955/000149315226009411/form10-k.htm). ## Lipocine annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$2.0 million](https://www.sec.gov/Archives/edgar/data/1535955/000149315226009411/) | [$11.2 million](https://www.sec.gov/Archives/edgar/data/1535955/000149315226009411/) | | Research and development | [$8.6 million](https://www.sec.gov/Archives/edgar/data/1535955/000149315226009411/) | [$7.4 million](https://www.sec.gov/Archives/edgar/data/1535955/000149315226009411/) | | Net income (loss) | [-$9.6 million](https://www.sec.gov/Archives/edgar/data/1535955/000149315226009411/) | [$8,352](https://www.sec.gov/Archives/edgar/data/1535955/000149315226009411/) | | Cash from operations | [-$9.8 million](https://www.sec.gov/Archives/edgar/data/1535955/000149315226009411/) | [-$1.2 million](https://www.sec.gov/Archives/edgar/data/1535955/000149315226009411/) | | Cash and equivalents | [$5.2 million](https://www.sec.gov/Archives/edgar/data/1535955/000149315226035909/) | [$6.2 million](https://www.sec.gov/Archives/edgar/data/1535955/000149315226009411/) | | Short-term investments | [$9.7 million](https://www.sec.gov/Archives/edgar/data/1535955/000149315226035909/) | [$15.4 million](https://www.sec.gov/Archives/edgar/data/1535955/000149315226009411/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $5.0 million, plus short-term investments of $18.3 million, $23.3 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Lipocine Has Lipocine raised money recently? Our latest story on this, dated Feb 26, 2026: "Lipocine raises its at-the-market program to $50,000,000". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/lipocine-raises-market-program-50-000-000/). What is the ticker symbol of Lipocine? Lipocine Inc. trades under the ticker LPCN on NASDAQ. Where is Lipocine listed? Lipocine Inc. is listed on NASDAQ. What is the SEC CIK of Lipocine? The SEC Central Index Key (CIK) for Lipocine Inc. is 1535955. Its filings are on SEC EDGAR. How many shares does Lipocine have outstanding? 8,244,253 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-04. Which country or territory is Lipocine listed under? Our directory records Lipocine Inc. under United States. What does Lipocine do? Our directory classifies Lipocine Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Lipocine? The ISIN recorded for Lipocine Inc. is US53630X2036. Does aibio.space cover Lipocine? aibio.space lists Lipocine Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Lipocine incorporated? SEC records list its state or country of incorporation as DE. What does Lipocine develop? Lipocine Inc. is a biopharmaceutical company that uses a proprietary technology platform to develop products with effective oral delivery of previously difficult to deliver molecules. Its lead product, TLANDO, is an oral treatment for testosterone replacement therapy in adult males with a deficiency or absence of endogenous testosterone, comprised of testosterone undecanoate. What is TLANDO from Lipocine? TLANDO: Oral testosterone undecanoate for testosterone replacement therapy in adult males Stage: Licensed to commercial partners in several territories. What is LPCN 1111 (TLANDO XR) from Lipocine? LPCN 1111 (TLANDO XR): Once-daily oral testosterone tridecanoate for testosterone replacement therapy Stage: Licensed to Verity for the United States and Canada. What was Lipocine's revenue last year? $2.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Lipocine profitable? Lipocine Inc. reported a net loss of $9.6 million for the fiscal year ended Dec 31, 2025, and used $9.8 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Lipocine Members talk about Lipocine (LPCN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Lipocine, newest first. Each line links the filing it comes from. 1. 2026-03-10 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1535955/000149315226009411/form10-k.htm) 2. 2026-02-26 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1535955/000149315226008201/form424b5.htm) 3. 2025-03-13 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1535955/000149315225010146/form10-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:LPCN on TradingView](https://www.tradingview.com/symbols/NASDAQ-LPCN/). ## SEC filings and registration - **SEC name**: Lipocine Inc. - **CIK**: 1535955 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: LPCN (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, United States, 84108 - **Phone**: 801 994 7383 - **Shares outstanding**: 8,244,253 as of 2026-08-03 (10-Q filed 2026-08-04) - **Former names**: MARATHON BAR CORP ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1535955/000149315226047693/form8-k.htm) filed 2026-10-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1535955/000149315226046060/form8-k.htm) filed 2026-10-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1535955/000149315226042933/form8-k.htm) filed 2026-09-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1535955/000149315226042466/form8-k.htm) filed 2026-09-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1535955/000149315226042286/form8-k.htm) filed 2026-09-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1535955/000149315226042052/form8-k.htm) filed 2026-09-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1535955/000149315226035913/form8-k.htm) filed 2026-08-04 - [10-Q](https://www.sec.gov/Archives/edgar/data/1535955/000149315226035909/form10-q.htm) filed 2026-08-04 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001535955), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Lipocine Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker LPCN, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Lipocine Inc. - **Ticker**: LPCN - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US53630X2036 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-LPCN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/lipocine/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Lipocine (LPCN) news: offering", 2026-10-31, https://aibio.space/companies/lipocine/